New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO-102 G
Go back to New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO-102 G| (NASDAQ: ABEO) | Delayed: 7.36 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.36 | 52 Week High | $9.44 | |||
| Open | $7.36 | 52 Week Low | $2.05 | |||
| Day High | $7.36 | P/E | N/A | |||
| Day Low | $7.36 | EPS | $0.00 | |||
| Volume | 28,136 | |||||
